Ensartinib

Drug Profile

Ensartinib

Alternative Names: X-396

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xcovery
  • Developer Betta Pharmaceuticals Co Ltd; Cancer Research Institute; Ludwig Institute for Cancer Research; MedImmune; National Cancer Institute (USA); Xcovery Holdings
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II CNS cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 Jul 2017 Phase-II clinical trials in Solid tumours, Non-Hodgkin's lymphoma and CNS cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (PO) (NCT03213652)
  • 24 Jul 2017 Xcovery collaborates with the National Cancer Institute and Children’s Oncology Group to provide ensartinib for the phase II Pediatric MATCH trial
  • 17 Jul 2017 Betta Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (Late stage, Metastatic disease, Second-line therapy or greater) in China (NCT03215693)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top